Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
A returning patient provides his fingerprint for a biometrics tracking system at an operation ASHA tuberculosis treatment center in 2011, in New Delhi, India. Photo: Andrew Caballero-Reynolds/Getty Images
The Food and Drug Administration on Wednesday approved Pretomanid Tablets, when used alongside 2 other antibiotics, to treat an extremely drug-resistant strain of tuberculosis.
Why it matters: "Tuberculosis has now surpassed AIDS as the world’s leading infectious cause of death," the New York Times reports. The new drug cured 89% of 107 patients with extensively drug-resistant TB after 6 months, when used in combination with antibiotics bedaquiline and linezolid, the FDA said.
What's new: Before the FDA approved this combination therapy, the most common treatment for this type of tuberculosis required patients to take around 30 pills a day plus sometimes daily injections for at least 18 months. This new treatment lowers that dose to 5 pills/day over 6 months for most patients.
- A spokesperson for the nonprofit TB Alliance, which submitted Pretomanid Tablets to the FDA based on 19 clinical trials, said "it'd be a stretch" to describe previous drug regimens for highly resistant forms of tuberculosis as effective treatment.
- "We've seen some incremental improvement, but until now, there hasn't been anything I would call a reliable cure," the spokesperson said.
The big picture: XDR-TB, or extensively drug-resistant tuberculosis, is found in over 127 countries. Tuberculosis is especially prevalent in India, South Africa and China. To a lesser extent, Brazil and Russia also have significant TB problems.
- Tuberculosis is responsible for 1 in 3 HIV deaths, per 2018 data from the World Health Organization.
- "It happens to be a disease that kills the poorest of the poor," a TB Alliance spokesperson said.
The bottom line: Although the new drug is now approved only in the U.S., FDA approval is a signal to the rest of the world that this treatment has validity.
Go deeper: Experts say eliminating TB is possible this generation, but funding is paramount
Editor's note: This story has been updated to correct 'XDR-TBD' to 'XDR-TB.'